title: Effects of neonatal injections of anti-CD3 epsilon monoclonal antibodies on the T cell functions of adult mice.
abstract: The effect of neonatal injections of anti-CD3 mAb on the subsequent immune responsiveness of adult mice has been investigated. The data indicate that neonatal treatment with three injections of 50 microliters of anti-CD3 epsilon ascitic fluid induce a profound depletion of T cells in the peripheral lymphoid organs but do not modify the absolute number of thymocytes. This treatment completely abolishes the T cell functions of mice at least 3 wk after the last injection of mAb. In the thymus, this suppression is associated with a decrease in the number of TcR/CD3 molecules in the dull CD3+ cells and with a drastic reduction the bright CD3+ population. However, the amount and the size of the TcR alpha,beta and CD3 epsilon mRNA transcripts are not modified, suggesting that the down-regulation of the TcR/CD3 complex induced by anti-CD3 mAb does not exert a feedback inhibition on the transcription of TcR genes. The suppression induced by neonatal injections of anti-CD3 epsilon mAb is reversible and the induction of immune responses requires the reappearance of a minimal number of bright CD3+ cells. However, this suppression can be maintained without side effects for several months provided that anti-CD3 mAb were administered at 7-day intervals from birth. This injection schedule should allow the study of the effect of anti-CD3 antibodies during the T cell ontogeny on the establishment of the B and T cell repertoires.
authors.affiliation: Département d'Immunologie, Institut Pasteur, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Rueff-Juy
authors.forename: A M
authors.initials: AM
authors.lastname: Drapier
authors.forename: P A
authors.initials: PA
authors.lastname: Cazenave
mesh_terms: D000375:Aging / Q000276:immunology; D000818:Animals; D000831:Animals, Newborn / Q000254:growth & development / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000917:Antibody Formation; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D017252:CD3 Complex; D004140:Dinitrophenols / Q000276:immunology; D005362:Ficoll / Q000031:analogs & derivatives / Q000276:immunology; D007106:Immune Sera / Q000032:analysis; D007274:Injections, Intraperitoneal; D008213:Lymphocyte Activation; D051379:Mice; D008819:Mice, Nude; D010047:Ovalbumin / Q000276:immunology; D010641:Phenotype; D011948:Receptors, Antigen, T-Cell / Q000032:analysis / Q000276:immunology*; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology* / Q000502:physiology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014301:Trinitrobenzenes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D004140:Dinitrophenols; D007106:Immune Sera; D011948:Receptors, Antigen, T-Cell; C020529:TNP-ficoll; D014301:Trinitrobenzenes; C045521:dinitrophenol-ovalbumin; D005362:Ficoll; D010047:Ovalbumin